kidney
-
Atrasentan helps slow chronic kidney disease
Abbott announced positive results from a phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy …
kidney | 01 February 2011
-
Millipore Launches Test Kits for Human Kidney Damage
Millipore introduces the Milliplex Multi-Analyte Profile (MAP) human kidney toxicity assay kits. According to Millipore, it is the first commercially available multiplex kits for human drug toxicity research, with biomarker panels revealing early si…
kidney | 03 June 2010
-
Novartis Receives Approval for Organ Rejection Prevention Drug
The US Food and Drug Administration (FDA) has approved Zortress (everolimus) oral tablets for the prevention of organ rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. The drug is to be given in combination with r…
kidney | 27 May 2010
-
Study Indicates Drug Effveness for Kidney Transplant Recipients
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a costimulation blocker can prevent the immune system from rejecting new organs. The results also suggest that it may provide similar patient and graft survival t…
kidney | 23 April 2010
-
FDA Advisory Committee Votes for Earlier use of Phosphate Binders in Stage 4 Kidney Disease
Patients with Hyperphosphatemia Majority of the members at the US Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee meeting voted to recommend the use of phosphate binders, including Shire Pharmaceuticals 
kidney | 01 November 2007
